Overview
VoxelCloud provides AI-powered software for medical imaging that helps hospitals, clinics, and research centers diagnose and treat diseases more accurately and efficiently. The software analyzes medical images, including 3D and live-action data, to support healthcare professionals in decision making and planning. It interoperates with existing imaging equipment through licensing and subscription models, delivering AI capabilities as part of a clinician’s workflow. Compared with competitors, VoxelCloud emphasizes practical augmentation of clinical workflows by tightly integrating with imaging devices, offering scalable licensing and ongoing updates to improve diagnostic accuracy and efficiency. The company aims to reduce healthcare costs and improve patient outcomes by enabling earlier detection and preventive care through augmented intelligence.
Work here?Claim your company
Simplify's take
What believers are saying
- 2026 NMPA approval strengthens sales with Chinese hospitals and reimbursement pathways.
- Existing customers include Peking Union, Ruijin, Tencent Health, and Mayo Clinic.
- Cross-modality products expand wallet share across imaging, screening, and follow-up workflows.
What critics are saying
- No recent news, layoffs, or product launches surfaced outside VoxelCloud’s own site.
- Last disclosed funding was 2019; prolonged silence signals weak capital access.
- Deepwise, Yizhun Intelligent, and Ultromics pressure VoxelCloud’s clinical AI niche.
What makes VoxelCloud unique
- VoxelCloud spans radiology, ophthalmology, and dermatology, not a single-disease workflow.
- Its 2026 site says NMPA approved class-III diabetic retinopathy software.
- It claims deployment across 300 medical institutions and 200,000 daily platform uses.
Help us improve and share your feedback! Did you find this helpful?